NASDAQ · HCAT
Healthcare · Medical - Healthcare Information Services
$1.76
Down-$0.01 (-0.56%)
Updated Oct 8, 2026, 4:55 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · HCAT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
HCAT closed at $1.76 after 21 trading sessions, up 1.73% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $1.75 | $1.785 | $1.724 | $1.76 | 240.67K |
| Oct 6, 2026 | $1.77 | $1.82 | $1.75 | $1.77 | 225.22K |
| Oct 5, 2026 | $1.75 | $1.79 | $1.725 | $1.76 | 230.25K |
| Oct 2, 2026 | $1.71 | $1.76 | $1.695 | $1.75 | 243.4K |
| Oct 1, 2026 | $1.73 | $1.775 | $1.70 | $1.70 | 348.96K |
| Sep 30, 2026 | $1.76 | $1.795 | $1.72 | $1.73 | 383.57K |
| Sep 29, 2026 | $1.74 | $1.765 | $1.695 | $1.75 | 393.27K |
| Sep 28, 2026 | $1.72 | $1.77 | $1.705 | $1.77 | 532.88K |
| Sep 25, 2026 | $1.73 | $1.765 | $1.73 | $1.74 | 116.95K |
| Sep 24, 2026 | $1.73 | $1.76 | $1.71 | $1.74 | 706.93K |
| Sep 23, 2026 | $1.87 | $1.87 | $1.72 | $1.72 | 197.96K |
| Sep 22, 2026 | $1.81 | $1.89 | $1.76 | $1.89 | 342.32K |
| Sep 21, 2026 | $1.79 | $1.81 | $1.76 | $1.81 | 315.42K |
| Sep 18, 2026 | $1.80 | $1.80 | $1.73 | $1.79 | 861K |
| Sep 17, 2026 | $1.80 | $1.845 | $1.76 | $1.80 | 563.56K |
| Sep 16, 2026 | $1.74 | $1.745 | $1.675 | $1.73 | 338.18K |
| Sep 15, 2026 | $1.81 | $1.82 | $1.705 | $1.72 | 350.65K |
| Sep 14, 2026 | $1.70 | $1.835 | $1.70 | $1.82 | 831.52K |
| Sep 11, 2026 | $1.75 | $1.77 | $1.69 | $1.70 | 264.26K |
| Sep 10, 2026 | $1.71 | $1.745 | $1.615 | $1.73 | 677.29K |
| Sep 9, 2026 | $1.68 | $1.765 | $1.65 | $1.73 | 582.43K |
The latest Smart Investors Daily articles mentioning HCAT.
Company
Market Activity
Research & News
HCAT research
Company profile and research snapshot.
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | Canaccord Genuity | Hold | — |
| Aug 13, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 11, 2026 | Citigroup | Neutral | — |
| Jul 21, 2026 | Canaccord Genuity | Buy | — |
| Jun 26, 2026 | Wells Fargo | Equal-Weight | — |
No generated briefing is available yet.
Yahoo · Sep 30, 2026
What a time it’s been for Health Catalyst. In the past six months alone, the company’s stock price has increased by a massive 48.7%, reaching $1.76 per share. This performance may have investors wondering how to approach the situation.
Yahoo · Sep 25, 2026
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Yahoo · Sep 19, 2026
Health Catalyst is back in focus after analysts revised fair value from about US$2.10 to roughly US$1.83 per share, which points to a more cautious stance on the stock. Recent research has shifted from earlier optimism with price targets in the US$2 to US$3 range to current levels closer to US$1.80, as analysts weigh execution risks around churn, divestitures and the durability of growth in its health technology offerings. In this article, you will see how these changing targets fit into the...
Yahoo · Sep 18, 2026
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HCAT.
